AAD VMX 2020 library
Interested in licensing this content?
Request .mp4 files of the session videos from the Academy's licensing team.Submit your request
Click on the links in the bulleted lists below to view individual presentations.
Micrographic Dermatologic Surgery (MDS) Subspecialty Certification Exam Prep Course
This is a question and explanation based, session covering the subjects in the MDS Exam Review Guide to assist in preparations for the American Board of Dermatology’s MDS Subspecialty Certification Exam.
This session reviews new and emerging therapeutics for patients with psoriasis, dyspigmentation, and hair diseases. The newest and what's hot in dermatology ranging from medical to cosmetic to surgical dermatology is addressed.
JAK Inhibitors: A New Frontier in Dermatology
The recent emergence of Janus kinase (JAK) inhibitors has led to new therapeutic options in dermatology. The application of JAK inhibitors to common dermatologic diseases, with significant unmet medical need, is presented, including the results of clinical trials and case series. The audience for this session is dermatologists who care for patients with vitiligo, atopic dermatitis, psoriasis, granuloma annulare and sarcoidosis, in addition to other conditions.
Therapeutic and Diagnostic Pearls
This session highlights important diagnostic and therapeutic pearls and is directed towards both novice and experienced clinicians. Information discussed is based on both peer-reviewed literature and the result of personal experience.
What's New in Dermatology
This session reviews new developments in dermatologic surgery, cosmetic dermatology, pediatric dermatology, and medical dermatology. Specific sessions present new information from acne, rosacea, hidradenitis, and psoriasis, and there will be a session devoted to systemic dermatologic therapy.
What's New in Dermatopathology
This symposium provides information regarding advances in key areas of dermatopathology. Histopathologic findings of COVID-19, neoplastic lesions, inflammatory dermatitis, recent acceptable use criteria, molecular techniques, translational research, and viral infections are covered.
This session provides the dermatologist with what is available now and what the future holds for aesthetics.
Hidradenitis Suppurativa/Acne Inversa (HS/AI): Current Medical and Surgical Management
This session reviews hidradenitis suppurativa (HS) epidemiology and comorbidities, and current concepts of pathogenesis. An evidence-based approach for the use of medical therapies for HS, including topical agents, antibiotics, non-antibiotic systemics and biologics, is discussed. An approach to HS pain management is also presented.
Skin of Color
This session provides attendees with insight into skin conditions more commonly seen in patients with skin of color and provide ways to better diagnose and manage these conditions. Disorders of pigmentation are covered.
This symposium is directed to both general dermatologists and those with a specific interest in nail disorders. The best experts in nail disorders from around the world present the most up to date data on essential aspects of nail disease.
Hair Disorders Made Easier
This session covers the basics of the patient evaluation for hair loss, including diagnostic tips, treatment pearls, ethnic hairstyling, surgical procedures, and clinicopathologic correlation. It is directed at all practitioners who see alopecia patients.
Systemic Therapies for Dermatologists: A Comprehensive Review and Update
This session provides cutting edge information on a potpourri of topics dermatologists are going to deal with this year. Topics covered include the use of cannabinoids in dermatology; systemic medications available to treat more aggressive non melanoma skin cancers; diagnosing and managing adverse effects associated with many of these newer medications; and, how to manage pain in the post opioid era.
This is an overview and update of the current major issues related to psoriasis treatment.
Making Teledermatology Work
Dermatologists have been at the forefront of telehealth for the past two decades. In light of current events, even more dermatologists are adopting telehealth services. The purpose of this webinar is to educate dermatologists on the implementation of telehealth in their practices with current regulations from the Centers for Medicare and Medicaid Services (CMS) in mind.
Late-breaking Research: Clinical Studies/Pediatric
The effect of adding combined oral contraceptives or metformin to laser hair removal treatment on the quality of life of polycystic ovarian syndrome patients with hirsutism; a randomized control trial: Dorgham Nevine, MD
Late-breaking Research: Procedural Dermatology
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI) for the Treatment of Dynamic Forehead Lines (FHL) Following Glabellar Line (GL) Injections: Jeremy B. Green MD
Late-breaking Research: Basic Science/Cutaneous Oncology/Pathology
Important Measures for Psoriasis beyond PASI 100 – Patient-Reported Symptoms and Molecular Data from Patients Treated with Guselkumab or Adalimumab – A Sub-analysis from VOYAGE 1&2: Andrew Blauvelt, MD, MBA
Late-breaking Research: Clinical Trials
Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week Phase 3, randomized, double-blinded, ustekinumab- and placebo-controlled study: Kristian Reich, MD, PhD
Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week Phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal: Kenneth Gordon, MD
Lebrikizumab, a High-Affinity IL-13 Inhibitor, Demonstrates Rapid and Clinically Meaningful Improvements in Quality of Life Measures in a Phase 2b Trial of Moderate-to-Severe Atopic Dermatitis Patients: Emma Guttman-Yassky, MD
Efficacy and safety of tralokinumab with concomitant topical corticosteroid in adult patients with moderate-to-severe atopic dermatitis: Results from the 32-week Phase 3 ECZTRA 3 trial: Jonathan Silverberg
A Phase 3, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 5% in Japanese Patients with Primary Axillary Hyperhidrosis: Tomoko Fujimoto, MD, PhD